ArticleFrontiers in oncology2024
Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Assessment measures for chemotherapy-induced peripheral neuropathy among pediatric oncology patients: an updated systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis.World journal of surgical oncology · 2025Pooled it
- Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial).International journal of cancer · 2026Trial
- Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.BMC pharmacology & toxicology · 2026Trial
- Limb cold therapy for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.World journal of surgical oncology · 2026Trial
- Evaluation of trimetazidine in alleviating paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial.Frontiers in pharmacology · 2026Trial
- Assessment of Chemotherapy-Induced Peripheral Neuropathy and Its Relationship to Breast Cancer Patients' Quality of Life.Maedica · 2026Article
- 8-Aminoguanine protects against paclitaxel-induced neural degeneration and mechanical allodynia.JCI insight · 2026Article
- Factors associated with peripheral neuropathy development during gemcitabine plus albumin-bound paclitaxel therapy as first-line treatment for unresectable pancreatic cancer: a retrospective evaluation.Journal of pharmaceutical health care and sciences · 2026Article
- Article
- Time-course based assessment of patient factors and their relationship to chemotherapy induced peripheral neuropathy.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Chemotherapy-induced peripheral neuropathy in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Risk prediction of severe chemotherapy-induced peripheral neuropathy in breast cancer patients receiving nab-paclitaxel: a clinical nomogram.Frontiers in pharmacology · 2026Article
- Risk factors and interrelationships of taxane-related peripheral neuropathy: a Bayesian network analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China: A Retrospective, Database, Multicenter Study (ReTARdant) Protocol.Pain and therapy · 2025Article
- Factors affecting chemotherapy-induced peripheral neuropathy in patients with breast cancer: a cross-sectional study in China.Translational cancer research · 2025Article
- Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Analysis of factors influencing chemotherapy-induced peripheral neuropathy in breast cancer patients using a random forest model.Breast (Edinburgh, Scotland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse reaction in taxane-based chemotherapy. This study aimed to analyze the risk factors of peripheral neuropathy in patients with breast cancer receiving paclitaxel chemotherapy to provide a reference for the early prevention of CIPN. Methods: We included 350 patients with breast cancer who received chemotherapy for the first time at the Tangshan People's Hospital between August 2022 and June 2023 and were followed for at least 3 months after the end of chemotherapy. The incidence of CIPN in patients with breast cancer was calculated, and risk factors for CIPN were analyzed using logistic regression analysis. Results: The incidence rate of CIPN was 79.1%. Multifactor logistic regression analysis indicated that age ≥45 years [odds ratio (OR)=5.119, 95% confidence interval (CI)=1.395-18.780] and ≥60 years (OR=9.366, 95% CI=1.228-71.421), history of hypertension (OR=3.475, 95% CI=1.073-11.250), cumulative dose of chemotherapy drugs >900 mg (OR=4.842, 95% CI=1.961-5.946), vitamin D deficiency (OR=6.214, 95% CI=2.308-16.729), abnormal alanine aminotransferase (OR=3.154, 95% CI=1.010-9.844), anemia before chemotherapy (OR=2.770, 95% CI=1.093-7.019), infusion duration of chemotherapy drugs >30 min (OR=3.673, 95% CI=1.414-9.539), body mass index ≥24 kg/m Conclusion: Clinical attention should be paid to patients with these risk factors, and active and effective preventive measures should be taken to reduce the occurrence of CIPN and improve the quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.